April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Prevention Of Experimental Autoimmune Uveoretinitis By Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate
Author Affiliations & Notes
  • Miho Osada
    The Jikei University, Tokyo, Japan
  • Tsutomu Sakai
    The Jikei University, Tokyo, Japan
  • Kana Kuroyanagi
    The Jikei University, Tokyo, Japan
  • Goichi Akiyama
    The Jikei University, Tokyo, Japan
  • Hideo Kohno
    The Jikei University, Tokyo, Japan
  • Hiroshi Tsuneoka
    The Jikei University, Tokyo, Japan
  • Footnotes
    Commercial Relationships  Miho Osada, None; Tsutomu Sakai, None; Kana Kuroyanagi, None; Goichi Akiyama, None; Hideo Kohno, None; Hiroshi Tsuneoka, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2955. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Miho Osada, Tsutomu Sakai, Kana Kuroyanagi, Goichi Akiyama, Hideo Kohno, Hiroshi Tsuneoka; Prevention Of Experimental Autoimmune Uveoretinitis By Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2955.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Peroxisome proliferator-activated receptor-α (PPARα) agonist fenofibrate (LIPIDIL®) has been shown to have anti-inflammatory activity and suppress the development of experimental autoimmune encepharomyelitis. In this study, we investigated the effect of PPARα agonist fenofibrate in experimental autoimmune uveoretinitis (EAU).

Methods: : Lewis rats were immunized with retinal S antigen peptide and the severity of EAU disease was scored. The PPARα agonist fenofibrate (20mg/kg/day) was orally administered every day from day 0 postimmunization until day 14. The eyes were obtained on day 21 postimmunization and the histological score was determined using pathological findings. The expression of inflammatory cytokines including IL-6, IL-17, and VEGF was determined immunohistochemically.

Results: : Systemically administered PPARα agonist fenofibrate suppressed the development of EAU. The clinical scores (control:fenofibrate) were 2.83±0.93:1.17±0.98 and 3.67±0.40:1.42±0.86 on day 17 and 21 postimmunization, respectively. PPARα agonist fenofibrate also decreased the histological scores and the expression of inflammatory cytokines in the retina of EAU.

Conclusions: : These results suggest that PPARα agonist fenofibrate may modulate the development of EAU and suppress intraocular inflammation by decreasing the production of inflammatory cytokines.

Keywords: uveitis-clinical/animal model • autoimmune disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×